Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection?

Ruf MT, Chauty A, Adeye A, Ardant MF, Koussemou H, Johnson RC, Pluschke G.

PLoS Negl Trop Dis. 2011 Aug;5(8):e1252. doi: 10.1371/journal.pntd.0001252. Epub 2011 Aug 2.

2.

Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.

Ruf MT, Schütte D, Chauffour A, Jarlier V, Ji B, Pluschke G.

Antimicrob Agents Chemother. 2012 Feb;56(2):687-96. doi: 10.1128/AAC.05543-11. Epub 2011 Dec 5.

3.

Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease.

Sarfo FS, Converse PJ, Almeida DV, Zhang J, Robinson C, Wansbrough-Jones M, Grosset JH.

PLoS Negl Trop Dis. 2013;7(3):e2101. doi: 10.1371/journal.pntd.0002101. Epub 2013 Mar 14.

4.

Immunosuppression and treatment-associated inflammatory response in patients with Mycobacterium ulcerans infection (Buruli ulcer).

Schütte D, Pluschke G.

Expert Opin Biol Ther. 2009 Feb;9(2):187-200. doi: 10.1517/14712590802631854 . Review.

PMID:
19236249
5.

Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin.

Schütte D, Um-Boock A, Mensah-Quainoo E, Itin P, Schmid P, Pluschke G.

PLoS Negl Trop Dis. 2007 Oct 31;1(1):e2.

6.

Phagocytosis of Mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions.

Schütte D, Umboock A, Pluschke G.

Br J Dermatol. 2009 Feb;160(2):273-83. doi: 10.1111/j.1365-2133.2008.08879.x. Epub 2008 Oct 22.

PMID:
19016694
7.

Histopathological changes and clinical responses of Buruli ulcer plaque lesions during chemotherapy: a role for surgical removal of necrotic tissue?

Ruf MT, Sopoh GE, Brun LV, Dossou AD, Barogui YT, Johnson RC, Pluschke G.

PLoS Negl Trop Dis. 2011 Sep;5(9):e1334. doi: 10.1371/journal.pntd.0001334. Epub 2011 Sep 27.

8.

Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine Mycobacterium ulcerans infection.

Martins TG, Gama JB, Fraga AG, Saraiva M, Silva MT, Castro AG, Pedrosa J.

PLoS One. 2012;7(2):e32740. doi: 10.1371/journal.pone.0032740. Epub 2012 Feb 29.

9.

Local Cellular Immune Responses and Pathogenesis of Buruli Ulcer Lesions in the Experimental Mycobacterium Ulcerans Pig Infection Model.

Bolz M, Ruggli N, Borel N, Pluschke G, Ruf MT.

PLoS Negl Trop Dis. 2016 Apr 29;10(4):e0004678. doi: 10.1371/journal.pntd.0004678. eCollection 2016 Apr.

10.

Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection.

Martins TG, Trigo G, Fraga AG, Gama JB, Longatto-Filho A, Saraiva M, Silva MT, Castro AG, Pedrosa J.

PLoS Negl Trop Dis. 2012;6(11):e1925. doi: 10.1371/journal.pntd.0001925. Epub 2012 Nov 29.

11.

Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase /IS 2404 qPCR assay.

Sarpong-Duah M, Frimpong M, Beissner M, Saar M, Laing K, Sarpong F, Loglo AD, Abass KM, Frempong M, Sarfo FS, Bretzel G, Wansbrough-Jones M, Phillips RO.

PLoS Negl Trop Dis. 2017 Jul 3;11(7):e0005695. doi: 10.1371/journal.pntd.0005695. eCollection 2017 Jul.

12.

Kinetics of mycolactone in human subcutaneous tissue during antibiotic therapy for Mycobacterium ulcerans disease.

Sarfo FS, Phillips RO, Zhang J, Abass MK, Abotsi J, Amoako YA, Adu-Sarkodie Y, Robinson C, Wansbrough-Jones MH.

BMC Infect Dis. 2014 Apr 15;14:202. doi: 10.1186/1471-2334-14-202.

13.

Secondary bacterial infections of buruli ulcer lesions before and after chemotherapy with streptomycin and rifampicin.

Yeboah-Manu D, Kpeli GS, Ruf MT, Asan-Ampah K, Quenin-Fosu K, Owusu-Mireku E, Paintsil A, Lamptey I, Anku B, Kwakye-Maclean C, Newman M, Pluschke G.

PLoS Negl Trop Dis. 2013 May 2;7(5):e2191. doi: 10.1371/journal.pntd.0002191. Print 2013.

14.

Vaccination with the Surface Proteins MUL_2232 and MUL_3720 of Mycobacterium ulcerans Induces Antibodies but Fails to Provide Protection against Buruli Ulcer.

Bolz M, Bénard A, Dreyer AM, Kerber S, Vettiger A, Oehlmann W, Singh M, Duthie MS, Pluschke G.

PLoS Negl Trop Dis. 2016 Feb 5;10(2):e0004431. doi: 10.1371/journal.pntd.0004431. eCollection 2016 Feb.

15.

Clinical outcomes of Ghanaian Buruli ulcer patients who defaulted from antimicrobial therapy.

Klis S, Kingma RA, Tuah W, van der Werf TS, Stienstra Y.

Trop Med Int Health. 2016 Sep;21(9):1191-6. doi: 10.1111/tmi.12745. Epub 2016 Jul 26.

PMID:
27456068
16.

Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease).

Kibadi K, Boelaert M, Fraga AG, Kayinua M, Longatto-Filho A, Minuku JB, Mputu-Yamba JB, Muyembe-Tamfum JJ, Pedrosa J, Roux JJ, Meyers WM, Portaels F.

PLoS Negl Trop Dis. 2010 Jul 6;4(7):e736. doi: 10.1371/journal.pntd.0000736.

17.

[Paradoxical reactions and responses during antibiotic treatment for Mycobacterium ulcerans infection (Buruli ulcer). Four cases from French Guiana].

Sambourg E, Dufour J, Edouard S, Morris A, Mosnier E, Reynaud Y, Sainte-Marie D, Nacher M, Guégan JF, Couppié P.

Ann Dermatol Venereol. 2014 Jun-Jul;141(6-7):413-8. doi: 10.1016/j.annder.2014.01.010. Epub 2014 Feb 24. French.

18.

Outcome of Streptomycin-Rifampicin treatment of Buruli Ulcer in two Ghanaian districts.

Iddrisah FN, Yeboah-Manu D, Nortey PA, Nyarko KM, Anim J, Antara SN, Kenu E, Wurapa F, Afari EA.

Pan Afr Med J. 2016 Oct 1;25(Suppl 1):13. doi: 10.11604/pamj.supp.2016.25.1.6203. eCollection 2016.

19.

Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.

Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, Tuah W, Awua-Boateng NY, Ampadu EO, Siegmund V, Schouten JP, Adjei O, Bretzel G, van der Werf TS.

Lancet. 2010 Feb 20;375(9715):664-72. doi: 10.1016/S0140-6736(09)61962-0. Epub 2010 Feb 3.

PMID:
20137805
20.

Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease).

Chauty A, Ardant MF, Adeye A, Euverte H, Guédénon A, Johnson C, Aubry J, Nuermberger E, Grosset J.

Antimicrob Agents Chemother. 2007 Nov;51(11):4029-35. Epub 2007 May 25.

Supplemental Content

Support Center